IP Library Patent Application 18485086
Patent Application
App. No. 18/485,086

USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/485,086
Abstract

Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.

Claims (31)

1 - 72 . (canceled)

73 . A method of improving forced vital capacity (FVC) in a human subject in need thereof comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.

74 . The method of claim 73 , wherein the FVC is increased by about 2% to about 8% after administration.

75 . The method of claim 73 , wherein the FVC is increased by about 8% to about 12% after administration.

76 . The method of claim 73 , wherein the volume of FVC is increased by about 20 ml to about 200 ml after administration.

77 . The method of claim 73 , wherein the volume of FVC is increased by about 200 ml to about 450 ml after administration.

78 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.

79 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.

80 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 75 mg/day.

81 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.

82 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.

83 . The method of claim 80 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 37.5 mg twice per day.

84 . The method of claim 81 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.

85 . The method of claim 82 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.

86 . A method of reducing the amount of mucus plugs in the airways of a human subject in need thereof comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.

87 . The method of claim 86 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.

88 . The method of claim 86 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.

89 . The method of claim 86 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 75 mg/day.

90 . The method of claim 86 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.

91 . The method of claim 86 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.

92 . The method of claim 89 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 37.5 mg twice per day.

93 . The method of claim 90 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.

94 . The method of claim 91 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.

95 . A method of improving a score on St. George's Respiratory Questionnaire (SGRQ) in a human subject in need thereof comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.

96 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.

97 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.

98 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 75 mg/day.

99 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.

100 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.

101 . The method of claim 99 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.

102 . The method of claim 100 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2025
From: KNOPP BIOSCIENCES LLC
To: ARETEIA THERAPEUTICS, INC.
Reel/Frame 073532/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2025
From: PRUSSIN, CALMAN PHILIP
To: KNOPP BIOSCIENCES, LLC
Reel/Frame 073533/0559 →